SimplicityBio’s vision is to be one of the world’s leading in-silico biomarker discovery companies, providing to our clients robust biomarkers with a biological meaning.

SimplicityBio helps biotech and medtech companies create robust signatures by using a panel of biomarkers based on omics data. Our clients use these signatures for instance to bring molecular diagnostic test to the market, or for patient stratification in order to develop more effective medicaments.

SimplicityBio technology has a track record of converting research into commercial multi-marker products for example from cancer diagnostics to selection and ranking of biomarkers.

SimplicityBio is a spin-off from the University of Applied Sciences, Western Switzerland and is incubated at the BioArk in Monthey.


Discovery is our passion

Miguel Barreto, Co-founder

Management Team

Miguel Barreto, PhD CTO and Co-founder

Miguel Barreto holds a Ph.D. in Information Systems from Lausanne University. He is an expert in machine learning and bioinformatics, and has been working with the technology powering SimplicityBio's proprietary platform for the past 5 years.

Matthew Hall, PhD CEO, Co-founder and Board member

Matthew Hall holds a Ph.D. in Biology from the University of Lausanne. He has applied his knowledge over the past years in the Next Generation Sequencing biotechnology industry.

Pedro Faustino, EMBA COO and Co-founder

Pedro Faustino holds an EMBA in Management of Technology from both the Swiss Federal Institute of Technology in Lausanne (EPFL) and HEC Lausanne. He has held several technical positions in various technology-based multinational companies.

Thierry Duvanel Director of Corporate Development

Thierry Duvanel holds a Bachelor in electrical engineering from the University of Applied Sciences, Western Switzerland and a Master of Sciences from the Swiss Federal Institute of Technology in Lausanne (EPFL). He was the co-founder and CEO of Augurix Diagnostics SA. He brings his experience in the diagnostics field as well as his entrepreneurship skills.

Imran Fanaswala Senior Bioinformatician

Imran Fanaswala holds degrees in Bioinformatics (ETH Zurich) and Computer Science (AUS). He brings his experience in machine learning, bioinformatics, and a passion for meeting deadlines with clean code.

Board of Directors

Vincent Bieri Board president

Vincent Bieri is co-founder and board member at Nexthink SA. He brings his knowledge in sales, marketing strategy and SaaS software product management in Analytics and Big Data.

Vincent Mutel Board member

Vincent Mutel is CEO, co-founder and board member at Inflamalps SA. He was co-founder, CEO and vice chairman of the board at Addex Pharmaceuticals SA. He brings his biotech market knowledge and experience in corporate governance.

Scientific Advisory Board

Prof. Carlos Peña Scientific advisor

Prof. Carlos Peña is a Professor in Computer Engineering at the University of Applied Sciences, Western Switzerland. His central professional interest concerns the possible, different, interfaces between life and engineering sciences.

Prof. Manuel Peitsch Scientific advisor

Prof. Manuel Peitsch is the co-founder and the chairman of the Board of the Swiss Institute of Bioinformatics. Manuel Peitsch is CSO and VP for "Biological Systems Research" at Philip Morris International R&D. Manuel joined PMI R&D after 8 years at Novartis.

MD, Prof. Thomas Matthes Scientific advisor

Medical doctor Thomas Matthes, is associated professor at the Geneva University Hospital and director of the Swiss school of Flow cytometry. His deep knowledge of oncology and haematology, gives him a first hand insight of the problems faced when looking to diagnose complex diseases.